Team - Lumiseek

Executive Management Team

We are a seasoned group of entrepreneurs with exceptional oncology, business and software development expertise.

Himabindu GaddipatiMD, EMTM

Chief Executive Officer

Dr. Gaddipati has more than 20 years of experience  in the oncology domain. She is a clinical oncologist and geneticist with basic science and clinical trial expertise. She holds a master’s degree from the Wharton Business School and has also served at the US FDA and National Cancer Institute. Dr Gaddipati’s expertise spans clinical, scientific, regulatory and commercialization realms of the cancer product development lifecycle. Over the past 2 decades she has treated patients with complex oncologic disorders and genetic conditions. She served as a visiting scientist in the division of molecular oncogenesis, Wistar Research Institute in Philadelphia. She gained valuable insight about the regulatory requirements for marketing approval of drugs in the division of oncology drugs products, US FDA. She brings a nuanced comprehension about the inherent challenges involved in integrating diverse expertise along the value chain. Her belief is that by addressing the inefficiencies along the translational spectrum exponential greater advancement can be achieved in cancer care.

Career highlights:

  • Fellowship in Clinical Oncology/Hematology, Case Western Reserve University: With a research focus in early phase clinical trials.
  • Fellowship in Genetics and Molecular Biology, Children’s Hospital of Philadelphia/University of Pennsylvania: With specific focus on clinical cancer genetics concurrently with basic science research.
  • Master’s Degree in Management and Technology from the Wharton School of Business and Technology Commercialization from the University of Pennsylvania, School of Engineering: Projects involved analysis of trends in the biopharma industry.
  • Reviewer at the Food and Drug Administration, US (FDA)- Division of Oncology Drug products: While participating in regulatory work she published a highly cited comprehensive study: Rare Cancer Drug Approvals: US FDA experience of 34 years.
  • Analyst and Reviewer for Small Business Innovation Research (SBIR) program, National Cancer Institute, US.
  • Degree in Technology Transfer, National Institutes of Health.
  • Co-Chair Biocom Oncology Committee: A group of more than 120 organizations in Southern California.

Mandar KulkarniPhD

Chief Scientific Officer

Dr. Kulkarni’s core scientific expertise includes cancer biology, molecular carcinogenesis, and genomics. He has held several senior management positions and has been instrumental in setting up several high-value collaborations with clinical and research oncologists. As an effective member of senior executive team he also brings with him experience in strategic leadership, developing a corporate culture, establishing new initiatives, and knowledge across most functional areas of startups.

Career highlights:

  • Doctorate in molecular carcinogenesis, Purdue University.
  • T32 NIH fellow at the Yale School of Medicine, where he received a young scientist award by ACLPS.
  • Senior scientist at M/Z Diagnostics – developed a diagnostic assay for rapid detection of MDR bacterial infections, managed business activity, obtained an NIH-SBIR grant as a PI, and was awarded a Young scientist award by the FSG.
  • Head of molecular biology and genomics at Sandor Lifesciences – managed a team of 13 members to design and execute over 80 projects across NGS, bioinformatics, and microarray.

Satish MedicettyBVSc, PhD, MBA

Chief Innovation Officer

Dr. Medicetty is a Consultant in Cleveland Clinic, Ohio and has a great vision to create impactful platforms that bring together right people to drive the future of science medicine. He is a biotech entrepreneur and his background include a unique blend of executive management, business development and scientific expertise.

Career highlights:

  • BVSc in Veterinary Medicine from A.N.G.R.A.University, India.
  • PhD from Kansas State University, Manhattan, KS.
  • MBA from Weatherhead School of Management, CWRU, Cleveland, OH.
  • Served as the Director of Stem Cell Research and Lab Operations, NeoStem Inc & also as the President at GTCBio.
  • Started the company- Neurotherapies LLC.
  • Served as Board Director & President & CEO for Renovo Neural Inc.

Larry StambaughBBA

Senior Business Advisor

Mr. Stambaugh is known for his visionary leadership in innovation and high-growth businesses. During his more than 40-year career Mr. Stambaugh’s visionary leader has built successful management teams around his ability to awaken the leader within his associates to have them achieve extraordinary results. Mr. Stambaugh has raised over $500 million of capital in private and public financing. He has taken a company public in both the U.S. and Europe. He has completed several strategic partnerships with Fortune 100 and other companies. As the founding principal at Apercu Partners, he currently serves as Chairman of selected entrepreneurial companies and mentor/coach to CEO’s and boards.

Career highlights:

  • As Chairman and CEO of Maxim Pharmaceuticals, Larry raised the market capitalization of the company from $15 million to $1.7 billion. The company conducted 18 clinical trials in 22 countries on three continents that led to the approval of a novel leukemia therapy.
  • Received the “Director of the Year” recognition an unprecedented three times for his work in corporate governance leadership and education.
  • Executive committee of the board for BIOCOM (The oldest and largest California life science industry trade organization) and recently named a Life Director for his contributions. He leads the organizations public policy committee and serves as board lead on the strategic planning committee.
  • He has served as Chairman and CEO of several public and private companies, including as the Managing Director at the Centre for Bioinspiration for the San Diego Zoo Global.

Loganathan DoraisamyMSc, PhD

Chief Technology Officer

Dr. Doraisamy has expertise in the areas of nano-bio technologies, biomarker detection, microfluidics and next generation sequencing technologies for healthcare and bio-defense. He has successfully led collaborations between various stakeholders such as biotech industry, university researchers, clinical and government laboratories, US government funding agencies, private investors and customers, enabling R&D, product development and commercialization.

Career highlights:

  • Principal Scientist and Director of R&D for multiple Chem-Bio Technology companies in US.
  • Experienced in the process of New Product Development and Commercialization for a wide variety of medical devices including molecular diagnostics, imaging and sequencing systems.
  • Served as Quality Leader driving companies to achieve ISO certification and helped processing regulatory approvals for Medical and Biosecurity Sensors.
  • Multi-disciplinary Inventor and Entrepreneur with awarded and pending patents covering areas of Sensors, Medical Technologies, Nanomaterials, Renewable Energy and Food technologies.
  • Winner of India’s Best Ph.D. Award for the Year 2000 from India Physics Association (IPA) has been leading a number of collaborative R&D and commercialization activities in India.

Kamala MaddaliDVM, PhD

Chief Visibility Officer

Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries.

Career highlights:

  • She holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.
  • She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture).
  • She brings extensive strategic expertise from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.
  • She currently plays a pivotal role in developing industry wide biopharma collaborations and companion diagnostics strategy at Cancer Genetics Inc.

Brett Pivoriunas

Director, Finance

Brett is a commercial banker in San Diego. He has expertise in the area of partnering with Healthcare organizations to acquire financing. Throughout his career, he has successfully funded over $200 million, ranging from initial seed/start-up financing, to mature traditional bank financing.

Anil KodaliMSc

Director, Platform Development

Mr. Kodali has over 23 years of IT experience in Life Sciences / Supply Chain Domain with strong delivery background with an excellent blend of technical and business skills. Experienced in setting strategy and overseeing the operations of various departments, developing and maintaining customer and partner relationships, building high-performing global application teams and ecosystems.

Career highlights:

  • B.E (Hons) Electrical & Electronics and M.Sc. (Hons) Physics from Birla Institute of Technology and Science (BITS), Pilani, India.
  • Certified Project Management Professional (PMP) and Certified Scrum Master (CSM).
  • He was Vice President of Services at TAKE Supply Chain for 8 years having end to end responsibility for multiple supply chain products (which include buyer/supplier collaboration in Procure-To-Pay and Order-To-Cash, Data Collection products that are integrated with multiple ERP’s) implementations , consulting, production customizations and customer support.
  • He worked for 13 years in Mahindra Satyam (now Tech Mahindra) at various customer engagements (including Pfizer Inc, Glaxo Smith Kline) playing roles from Delivery Manager to Project Manager managing/leading large global teams on various technology/services engagements.
Plans Register